張珊珊 季一飛 蒲超
[摘要] 目的 探討有氧運(yùn)動(dòng)聯(lián)合葉酸治療對(duì)阿爾茨海默?。ˋD)患者認(rèn)知功能及血清細(xì)胞因子、血清同型半胱氨酸(Hcy)的影響。 方法 選擇2016年5月~2018年1月四川省南充市中心醫(yī)院診治的86例AD患者作為研究對(duì)象,依據(jù)隨機(jī)數(shù)字表法分為對(duì)照組和觀察組,每組各43例。對(duì)照組給予鹽酸多奈哌齊治療+有氧運(yùn)動(dòng)訓(xùn)練,觀察組在對(duì)照組基礎(chǔ)上聯(lián)合葉酸治療,療程為3個(gè)月。采用簡明精神狀態(tài)量表(MMSE)、阿爾茨海默病評(píng)價(jià)量表-認(rèn)知分表(ADAS-cog)評(píng)定患者的認(rèn)知功能,比較兩組治療前后血清Hcy、白細(xì)胞介素-6(IL-6)、IL-1β、腫瘤壞死因子-α(TNF-α)水平。 結(jié)果 治療前兩組MMSE評(píng)分、ADAS-cog評(píng)分比較,差異無統(tǒng)計(jì)學(xué)意義(P > 0.05)。治療后,兩組MMSE評(píng)分高于治療前,且觀察組高于對(duì)照組;兩組ADAS-cog評(píng)分低于治療前,且觀察組低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(均P < 0.05)。治療前兩組血清細(xì)胞因子水平、血清Hcy水平比較,差異無統(tǒng)計(jì)學(xué)意義(P > 0.05)。治療后,兩組血清IL-6、TNF-α、IL-1β水平低于治療前,且觀察組低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(均P < 0.05)。治療后,觀察組血清Hcy水平低于治療前,且觀察組低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(均P < 0.05)。結(jié)論 葉酸聯(lián)合有氧運(yùn)動(dòng)訓(xùn)練可更為有效地改善AD患者的認(rèn)知功能,可能與下調(diào)血清Hcy水平、抑制促炎癥細(xì)胞因子分泌有關(guān)。
[關(guān)鍵詞] 阿爾茨海默病;同型半胱氨酸;葉酸;有氧運(yùn)動(dòng)
[中圖分類號(hào)] R749.16? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1673-7210(2020)03(b)-0084-04
[Abstract] Objective To implore the effect of aerobic exercise combined with folic acid on cognitive function, serum cytokines and homocysteine (Hcy) in patients with Alzheimer′s disease (AD). Methods From May 2016 to January 2018, 86 cases with AD who treated in Nanchong City Central Hospital of Sichuan Province were selected. They were divided into control group and observation group according to the random number table method, with 43 cases in each group. Control group was treated with Donepezil Hydrochloride combine with aerobic exercise training, while observation group was treated with folic acid on the basis of control group. Both groups were treated for 3 months. Mini-mental state scale (MMSE) and the Alzheimer′s disease rating scale-cognitive sub-table (ADAS-cog) were used to evaluate the cognitive function of the patients. Serum levels of Hcy, interleukin-6 (IL-6), IL-1β and tumor necrosis factor-α (TNF-α) before and after treatment were compared between two groups. Results There was no significant difference in MMSE scores and ADAS-cog scores between two groups before treatment (P > 0.05). After treatment, MMSE scores in two groups were higher than those before treatment, and observation group were higher than control group. ADAS-cog scores of two groups were lower than those before treatment, and observation group was lower than control group, with statistically significant differences (all P < 0.05). There was no significant difference in serum cytokine levels and serum Hcy levels between two groups before treatment (P > 0.05). After treatment, serum levels of IL-6, TNF-α and IL-1β in two groups were lower than those before treatment, and observation group were lower than control group, with statistically significant differences (all P < 0.05). The serum Hcy level in observation group was lower than that before treatment, and observation group was lower than control group, with statistically significant difference (all P < 0.05). Conclusion Folic acid combined with aerobic exercise training can more effectively improve the cognitive function of AD patients, which may be related to the down-regulation of serum Hcy levels and the suppression of secretion of pro-inflammatory cytokines.
[Key words] Alzheimer′s disease; Homocysteine; Folic acid; Aerobic exercise
阿爾茨海默?。ˋD)是中樞神經(jīng)系統(tǒng)變性疾病,該病起病隱匿,進(jìn)展緩慢,最終可致患者生活無法自理。中國是人口大國,隨著人口老齡化加劇,AD的發(fā)病率也將隨之增高。因此,AD已成為中國面臨的重大公共健康問題之一。迄今為止,尚未發(fā)現(xiàn)有效的藥物治療方法,而非藥物干預(yù)措施如營養(yǎng)補(bǔ)充、有氧運(yùn)動(dòng)等方式受到越來越多的關(guān)注。國內(nèi)外研究發(fā)現(xiàn)[1-2],高同型半胱氨酸(Hcy)血癥可能與AD的發(fā)病及疾病進(jìn)展有關(guān)。葉酸可降低AD患者血清Hcy水平,使其病情得到緩解[3]。有氧運(yùn)動(dòng)可能有預(yù)防及延緩AD進(jìn)展的作用[4]。本研究旨在探討葉酸聯(lián)合有氧運(yùn)動(dòng)治療AD患者的臨床效果及對(duì)AD患者血清中細(xì)胞因子、Hcy的影響,為AD防治提供新思路。
1 資料與方法
1.1 一般資料
選取2016年5月~2018年1月四川省南充市中心醫(yī)院(以下簡稱“我院”)診治的86例AD患者作為研究對(duì)象,依據(jù)隨機(jī)數(shù)字表法分為對(duì)照組和觀察組,每組各43例。對(duì)照組,男23例,女20例;年齡59~70歲,平均(64.86±5.14)歲;平均受教育時(shí)間(9.32±2.78)年。觀察組,男22例,女21例;年齡61~70歲,平均(65.12±4.88)歲;平均受教育時(shí)間(8.94±2.65)年。兩組一般資料比較,差異無統(tǒng)計(jì)學(xué)意義(P > 0.05),具有可比性。本研究經(jīng)我院醫(yī)學(xué)倫理委員會(huì)批準(zhǔn),并取得患者監(jiān)護(hù)人的書面知情同意。
納入標(biāo)準(zhǔn):①符合AD診斷標(biāo)準(zhǔn)[5];②簡明精神狀態(tài)量表(MMSE)評(píng)分[6]10~27分;③Hachinski缺血指數(shù)量表(HIS)評(píng)分[7]≤4分。排除標(biāo)準(zhǔn):①其他神經(jīng)系統(tǒng)疾病、代謝性疾病、中毒等所致癡呆;②合并嚴(yán)重心、肺疾病,骨科疾病等不能配合參加運(yùn)動(dòng)者;③近期服用B族維生素、葉酸者;④血壓>160/90 mmHg(1 mmHg=0.133 kPa)。
1.2 方法
對(duì)照組給予鹽酸多奈哌齊[衛(wèi)材(中國)藥業(yè)有限公司,批號(hào):1503025]5 mg,1次/d,睡前服用+有氧運(yùn)動(dòng)訓(xùn)練,觀察組在對(duì)照組基礎(chǔ)上聯(lián)合葉酸片(常州制藥廠有限公司,批號(hào):32023302)5 mg,1次/d,治療周期為3個(gè)月。
有氧運(yùn)動(dòng)方法:我院康復(fù)師對(duì)患者進(jìn)行心肺運(yùn)動(dòng)預(yù)評(píng)估,制訂運(yùn)動(dòng)方案及運(yùn)動(dòng)強(qiáng)度,并進(jìn)行全程監(jiān)督及運(yùn)動(dòng)指導(dǎo)。有氧運(yùn)動(dòng)強(qiáng)度:中等(最大運(yùn)動(dòng)負(fù)荷時(shí)心率的70%)。運(yùn)動(dòng)方式:跑步(熱身10 min,跑步30 min,放松10 min),每周3次,持續(xù)3個(gè)月。
1.3觀察指標(biāo)
1.3.1 兩組認(rèn)知功能比較? 采用MMSE及阿爾茨海默病評(píng)價(jià)量表-認(rèn)知分表(ADAS-cog)評(píng)估AD患者的認(rèn)知功能[6,8]。MMSE量表主要對(duì)定向力、記憶力、注意力、計(jì)算力、回憶能力、語言能力等相關(guān)內(nèi)容進(jìn)行評(píng)價(jià),總分30分。<27分提示有認(rèn)知功能障礙。ADAS-cog量表對(duì)單詞回憶、命名、指令、結(jié)構(gòu)性練習(xí)、意向性練習(xí)、定向、單詞辨認(rèn)、回憶測(cè)驗(yàn)指令、口語能力、找詞困難、語言理解能力、注意力等內(nèi)容進(jìn)行評(píng)價(jià),總分70分。分?jǐn)?shù)越高,認(rèn)知功能損害越重。
1.3.2 兩組血清Hcy、細(xì)胞因子比較? 采用日立全自動(dòng)生化分析儀(型號(hào):日立7600)分析血清Hcy水平(深圳奧薩制藥有限公司,批號(hào):20160322);酶聯(lián)免疫吸附試驗(yàn)檢測(cè)白細(xì)胞介素(IL)-6、IL-1β、腫瘤壞死因子-α(TNF-α)水平(上海西唐生物科技有限公司,批號(hào):20160412)。
1.4 統(tǒng)計(jì)學(xué)方法
采用SPSS 21.0統(tǒng)計(jì)學(xué)軟件進(jìn)行數(shù)據(jù)分析,計(jì)量資料用均數(shù)±標(biāo)準(zhǔn)差(x±s)表示,兩組間比較采用t檢驗(yàn);計(jì)數(shù)資料組間比較采用χ2檢驗(yàn)。以P < 0.05為差異有統(tǒng)計(jì)學(xué)意義。
2 結(jié)果
2.1 兩組認(rèn)知功能比較
治療前兩組MMSE評(píng)分、ADAS-cog評(píng)分比較,差異無統(tǒng)計(jì)學(xué)意義(P > 0.05)。治療后,兩組MMSE評(píng)分高于治療前,且觀察組高于對(duì)照組;兩組ADAS-cog評(píng)分低于治療前,且觀察組低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(均P < 0.05)。見表1。
2.2 兩組血清細(xì)胞因子水平比較
治療前兩組血清細(xì)胞因子水平比較,差異無統(tǒng)計(jì)學(xué)意義(P > 0.05)。治療后,兩組血清IL-6、TNF-α、IL-1β水平低于治療前,且觀察組低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(均P < 0.05)。見表2。
2.3 兩組血清Hcy水平比較
治療前,兩組血清Hcy水平比較,差異無統(tǒng)計(jì)學(xué)意義(P > 0.05)。治療后,對(duì)照組血清Hcy水平與治療前比較,差異無統(tǒng)計(jì)學(xué)意義(P > 0.05);觀察組血清Hcy水平低于治療前,且觀察組低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(均P < 0.05)。見表3。
3 討論
AD以不可逆的記憶力、認(rèn)知功能下降,人格改變及精神癥狀為主要臨床表現(xiàn),嚴(yán)重影響患者的日常生活,給家庭及社會(huì)均帶來巨大的負(fù)擔(dān)[9-12]。流行病學(xué)資料顯示[13],由于缺乏有效治療手段,AD的死亡率逐年增長。據(jù)統(tǒng)計(jì),目前全球約5000萬AD患者,主要集中在發(fā)展中國家,每年用于AD防治的醫(yī)療費(fèi)用高達(dá)3150億美元[14]。因此,尋找預(yù)防及延緩AD疾病進(jìn)展的有效干預(yù)手段顯得尤為重要。目前,用于臨床治療的藥物多為β-淀粉樣蛋白(Aβ)、Tau蛋白的靶向藥物,治療效果欠佳,采用非藥物干預(yù)手段是當(dāng)前關(guān)注的熱點(diǎn)。與藥物比較,營養(yǎng)補(bǔ)充及運(yùn)動(dòng)具有較少的副作用和更好的依從性。既往研究發(fā)現(xiàn)[15],有氧運(yùn)動(dòng)可改善AD患者的腦血流量,增加海馬、額葉、頂葉和扣帶回皮層的體積,改善神經(jīng)發(fā)生。本研究結(jié)果顯示,有氧運(yùn)動(dòng)可改善AD患者的認(rèn)知功能,聯(lián)合葉酸治療可進(jìn)一步改善患者的認(rèn)知。
近來研究發(fā)現(xiàn)[16],高Hcy水平與AD的發(fā)病及疾病進(jìn)展可能有關(guān)。高Hcy水平可增加Aβ的神經(jīng)毒性;增加磷酸化Tau蛋白的聚集;直接損害血管內(nèi)皮,促進(jìn)氧自由基生產(chǎn),激活氧化應(yīng)激等,引起認(rèn)知功能障礙[17-19]。課題組前期研究發(fā)現(xiàn)[2],AD患者血清Hcy水平顯著升高,且與患者的癡呆程度成正比,是AD發(fā)病的獨(dú)立危險(xiǎn)因素。葉酸是Hcy代謝途徑中的輔助因子,葉酸缺乏導(dǎo)致甲基化周期中甲基供體的利用率降低,引起Hcy蓄積?;艨℃玫萚3]研究發(fā)現(xiàn),葉酸可加速AD患者的Hcy代謝,使血清Hcy水平降低,改善AD患者認(rèn)知功能,本研究也得到一致結(jié)果。目前,關(guān)于有氧運(yùn)動(dòng)對(duì)血清Hcy水平的影響存在爭議,根據(jù)受試者的運(yùn)動(dòng)類型,持續(xù)時(shí)間,運(yùn)動(dòng)強(qiáng)度,運(yùn)動(dòng)計(jì)劃的不同,結(jié)果不同。一項(xiàng)薈萃分析[20]指出,急性運(yùn)動(dòng)會(huì)顯著增加血清Hcy水平,但長期耐力運(yùn)動(dòng)對(duì)其無影響。張藍(lán)予等[21]研究發(fā)現(xiàn),長期堅(jiān)持騎行和長跑運(yùn)動(dòng)可以降低Hcy水平,降低高Hcy水平的發(fā)生率。本研究結(jié)果顯示,長期有氧運(yùn)動(dòng)對(duì)AD患者血清Hcy水平無影響,補(bǔ)充葉酸治療后血清Hcy水平顯著下降,提示適當(dāng)攝入葉酸有助于維持低血Hcy濃度,高強(qiáng)度運(yùn)動(dòng)期間對(duì)代謝的需求增加。
免疫調(diào)控假說可能是AD的發(fā)病機(jī)制之一[22]。AD的主要病理表現(xiàn)為Aβ沉積,其可激活小膠質(zhì)細(xì)胞,促進(jìn)炎性細(xì)胞因子釋放,損傷神經(jīng)元。持續(xù)激活會(huì)導(dǎo)致小膠質(zhì)細(xì)胞結(jié)合和吞噬Aβ的效率降低,Aβ降解酶活性降低,進(jìn)而導(dǎo)致其清除Aβ斑塊的能力降低,加劇Aβ沉積,形成惡性循環(huán)[23]。TNF-α、IL-6、IL-1β是AD中最重要的促炎細(xì)胞因子。TNF-α主要由單核細(xì)胞、巨噬細(xì)胞釋放,在細(xì)胞因子級(jí)聯(lián)反應(yīng)的啟動(dòng)和調(diào)節(jié)中發(fā)揮核心作用;IL-1β是大腦炎癥級(jí)聯(lián)反應(yīng)中的“主要調(diào)節(jié)劑”,可調(diào)節(jié)其他促炎細(xì)胞因子的表達(dá);IL-6對(duì)于神經(jīng)元組織的正常穩(wěn)態(tài)至關(guān)重要[24]。既往研究發(fā)現(xiàn)[25-26],AD患者腦組織中均伴有IL-6、TNF-α、IL-1β升高,長期規(guī)律的有氧運(yùn)動(dòng)干預(yù),可使其濃度明顯下降。本研究結(jié)果顯示,長期規(guī)律的有氧運(yùn)動(dòng)聯(lián)合葉酸治療可有效減少促炎因子的釋放,推測(cè)與葉酸降低血清Hcy水平有關(guān)。
綜上所述,葉酸聯(lián)合有氧運(yùn)動(dòng)訓(xùn)練可更為有效地改善AD患者的認(rèn)知功能,其可能與下調(diào)血清Hcy水平、抑制促炎細(xì)胞因子分泌有關(guān)。但是,葉酸聯(lián)合有氧運(yùn)動(dòng)通過何種途徑抑制大腦的慢性炎癥需進(jìn)一步深入研究。同時(shí),葉酸聯(lián)合有氧運(yùn)動(dòng)是否可延緩AD進(jìn)展需進(jìn)一步長期追蹤隨訪研究。
[參考文獻(xiàn)]
[1]? Farina N,Jernerén F,Turner C,et al. Homocysteine concentrations in the cognitive progression of Alzheimer′s disease [J]. Exp Gerontol,2017,99(1):146-150.
[2]? 張珊珊,季一飛,龍繼發(fā),等.阿爾茨海默病患者血Hcy與UA水平的變化及意義[J].西部醫(yī)學(xué),2019,31(6):863-866,872.
[3]? 霍俊婷,宋士萍,李薇,等.葉酸和維生素B12輔助治療對(duì)阿爾茨海默病患者認(rèn)知功能及血清細(xì)胞因子、神經(jīng)遞質(zhì)的影響[J].疑難病雜志,2019,18(2):123-126.
[4]? Kim MJ,Han CW,Min KY,et al. Physical exercise with multicomponent cognitive intervention for older adults with Alzheimer′s disease:a 6-month randomized controlled trial [J]. Dement Geriatr Cogn Dis Extra,2016,6(2):222-232.
[5]? Shabsigh R,Rowland D. The Diagnostic and Statistical Manual of Mental Disorders,fourth edition,text revision as an appropriate diagnostic for premature ejaculation [J]. J Sex Med,2007,4(5):1468-1478.
[6]? 張明園.精神科評(píng)定量表手冊(cè)[M].2版.長沙:湖南科學(xué)技術(shù)出版社,1998:121-126.
[7]? Hachinski VC,Liff LD,Zihka E,et al. Cerebral blood flow in dementia [J].Arch Neurol,1975,32(29):632-637.
[8]? Chu LW,Chiu KC,Hui SL,et al. The reliability and validity of the Alzheimer′s Disease Assessment Scale Cognitive Subscale (ADAS-Cog) among the elderly Chinese in Hong Kong [J]. Ann Acad Med Singapore,2000,29(4):474-485.
[9]? 立偉.阿爾茨海默病患者腦電圖表現(xiàn)與認(rèn)知功能的相關(guān)性分析[J].中外醫(yī)學(xué)研究,2018,16(28):60-62.
[10]? 張記春,黃庚娣,孟雪,等.阿爾茨海默病轉(zhuǎn)基因小鼠極早期嗅覺工作記憶的損害特征[J].中國實(shí)驗(yàn)動(dòng)物學(xué)報(bào),2018,26(4):437-443.
[11]? 李慧君,李超,畢鵬翔,等.血管性認(rèn)知障礙發(fā)病機(jī)制的研究進(jìn)展[J].中國現(xiàn)代醫(yī)生,2019,57(5):158-163.
[12] 張齊皓,劉辰庚,王培昌,等.腦脊液酶譜在阿爾茨海默病中的研究進(jìn)展[J].中國醫(yī)藥導(dǎo)報(bào),2019,16(14):19-22.
[13]? Alzheimer′s Association. 2016 Alzheimer′s disease facts and figures [J]. Alzheimers Dement,2016,12(4):459-509.
[14]? World Alzheimer Report 2018:The state of the art of dementia research:New frontiers [EB/OL]. [2018-04-42]. http://www.alz.co.uk/research/statistics Alzheimer′s Association.
[15]? Cass SP. Alzheimer′s Disease and Exercise:A Literature Review [J]. Curr Sports Med Rep,2017,16(1):19-22.
[16]? Baroni L,Bonetto C,Rizzo G,et al. Association Between Cognitive Impairment and Vitamin B12,F(xiàn)olate,and Homocysteine Status in Elderly Adults:A Retrospective Study [J]. J Alzheimers Dis,2019,70(2):443-453.
[17]? Shirafuji N,Hamano T,Yen SH,et al. Homocysteine Increases Tau Phosphorylation,Truncation and Oligomerization [J]. Int J Mol Sci,2018,19(3):891.
[18]? Larsson SC,Traylor M,Malik R,et al. Modifiable pathways in Alzheimer′s disease:Mendelian randomisation analysis [J]. BMJ,2017,359:j5375.
[19]? Janel N,Alexopoulos P,Badel A,et al. Combined assessment of DYRK1A,BDNF and homocysteine levels as diagnostic marker for Alzheimer′s diseas [J]. Transl Psychiatry,2017,7(6):e1154.
[20]? Deminice R,Ribeiro DF,F(xiàn)rajacomo FT. The Effects of Acute Exercise and Exercise Training on Plasma Homocysteine:A Meta-Analysis [J]. PLoS One,2016,11(3):e0151653.
[21]? 張藍(lán)予,陳濤.健身運(yùn)動(dòng)對(duì)中老年人同型半胱氨酸水平影響的研究[J].遼寧體育科技,2017,39(3):34-36.
[22]? 彭也,朱天碧,張釗,等.阿爾茨海默病的免疫調(diào)控研究進(jìn)展[J].中國藥理學(xué)通報(bào),2019,35(4):445-451.
[23]? Ahmad MH,F(xiàn)atima M,Mondal AC. Influence of microglia and astrocyte activation in the neuroinflammatory pathogenesis of Alzheimer′s disease:Rational insights for the therapeutic approaches [J]. J Clin Neurosci,2019,59:6-11.
[24]? Kinney JW,Bemiller SM,Murtishaw AS,et al. Inflammation as a central mechanism in Alzheimer′s disease [J]. Alzheimers Dement(NY),2018,4:575-590.
[25]? Raj D,Yin Z,Breur M,et al. Increased white matter inflammation in aging- and Alzheimer′s disease brain [J]. Front Mol Neurosci,2017,30(10):206-224.
[26]? 楊坤芳,謝曉燕,杜昊英,等.有氧運(yùn)動(dòng)訓(xùn)練對(duì)AD患者胰島素抵抗、血脂代謝及炎癥反應(yīng)的影響[J].海南醫(yī)學(xué)院學(xué)報(bào),2017,23(15):2044-2047.
(收稿日期:2019-10-21? 本文編輯:劉明玉)